Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM
Sarcoid is the most common tumor in horses all over the world. The sarcoid is a benign, locally invasive, usually fibroblastic proliferative skin neoplasm. Even if the etiology is not completley verified, the epidemiology and clinical behavior suggest a infectious intervention, probably BPV type 1 o...
| Autor principal: | |
|---|---|
| Formato: | Otro |
| Lenguaje: | sueco sueco |
| Publicado: |
2008
|
| Materias: | |
| Acceso en línea: | https://stud.epsilon.slu.se/11759/ |
| _version_ | 1855571933150576640 |
|---|---|
| author | Pettersson, Carina |
| author_browse | Pettersson, Carina |
| author_facet | Pettersson, Carina |
| author_sort | Pettersson, Carina |
| collection | Epsilon Archive for Student Projects |
| description | Sarcoid is the most common tumor in horses all over the world. The sarcoid is a benign, locally invasive, usually fibroblastic proliferative skin neoplasm. Even if the etiology is not completley verified, the epidemiology and clinical behavior suggest a infectious intervention, probably BPV type 1 or type 2. However, it is known that the cause is multifactorial. A genetic prepdispositon has been identified associated to genes within the Major Histocompatibility Complex (MHC), but also to breed, age and perhaps gender. There is also a proved connection between skin-trauma and development of sarcoids. This type of neoplasm tend to develop in areas of thin skin, such as the face, distal limbs and ventral parts of thorax, abdomen and genital areas. There are six saroid types identified makroscopically; occult, nodular, verrucous, fibroblastic, mixed sarcoid and malevolent. However a biopsy for histopathology is needed to verify the diagnosis. There are several treatment options available (surgery, cryosurgery, hyperthermia, radiation, chemotherapy and immunotherapy), but their use may be limited depending on the type of sarcoid, size, area affected, localization, available equipment and environmental safety. Sarcoids are also known for a high reoccurence rate after treatment.
This study compares and analysis the effects of Aldara™ and Xxterra™. Aldara™ is a verified immunotherapy, whereas the exact mechanism of action for Xxterra™ is not verified, though according to the producer Xxterra™ is also an immunotherapy. With this type of treatment the local immune system will be stimulated to reduce tumour cells and virus. The purpose of this study was to find a simple and effective treatment with a low rate of reoccurency. The study enrolled 19 horses with a total of 130 tumours. Of these tumors, 41 where treated and the rest were used as untreated controls. Seventeen horses with 30 tumours were treated with Aldara™ and 10 horses with 15 tumours were treated with Xxterra™. Eight of the horses with multiple sarcoids were treated with both ointments.
Of the 30 tumors treated with Aldara™ 27 tumors (90%) has so far responded with size reduction or total regression. The 3 tumors that didn´t respond to treatment were all fibroblastic sarcoids localized to the distal limbs on one horse. Of the 15 tumors treated with Xxterra™ 14 tumors (93%) has so far responded with size reduction or total regression. The tumor that didn´t respond to treatment was an occult sarcoid localized to the shoulder. In all the tumors that didn´t respond to treatment a change of medicine was made, after a treatment free period of at least 12 weeks, which immedately lead to a reduction in size. All the tumors has so far responded to at least one of the treatments.
The preliminary results of these two types of treatments are encouraging, though the number of horses included in the study is small. An extended study, comprising more horses and longer periods of follow-up, is required to be able to corroborate these conclusions. |
| format | Otro |
| id | RepoSLU11759 |
| institution | Swedish University of Agricultural Sciences |
| language | Swedish swe |
| publishDate | 2008 |
| publishDateSort | 2008 |
| record_format | eprints |
| spelling | RepoSLU117592017-10-17T11:39:52Z https://stud.epsilon.slu.se/11759/ Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM Pettersson, Carina Miscellaneous animal disorders Sarcoid is the most common tumor in horses all over the world. The sarcoid is a benign, locally invasive, usually fibroblastic proliferative skin neoplasm. Even if the etiology is not completley verified, the epidemiology and clinical behavior suggest a infectious intervention, probably BPV type 1 or type 2. However, it is known that the cause is multifactorial. A genetic prepdispositon has been identified associated to genes within the Major Histocompatibility Complex (MHC), but also to breed, age and perhaps gender. There is also a proved connection between skin-trauma and development of sarcoids. This type of neoplasm tend to develop in areas of thin skin, such as the face, distal limbs and ventral parts of thorax, abdomen and genital areas. There are six saroid types identified makroscopically; occult, nodular, verrucous, fibroblastic, mixed sarcoid and malevolent. However a biopsy for histopathology is needed to verify the diagnosis. There are several treatment options available (surgery, cryosurgery, hyperthermia, radiation, chemotherapy and immunotherapy), but their use may be limited depending on the type of sarcoid, size, area affected, localization, available equipment and environmental safety. Sarcoids are also known for a high reoccurence rate after treatment. This study compares and analysis the effects of Aldara™ and Xxterra™. Aldara™ is a verified immunotherapy, whereas the exact mechanism of action for Xxterra™ is not verified, though according to the producer Xxterra™ is also an immunotherapy. With this type of treatment the local immune system will be stimulated to reduce tumour cells and virus. The purpose of this study was to find a simple and effective treatment with a low rate of reoccurency. The study enrolled 19 horses with a total of 130 tumours. Of these tumors, 41 where treated and the rest were used as untreated controls. Seventeen horses with 30 tumours were treated with Aldara™ and 10 horses with 15 tumours were treated with Xxterra™. Eight of the horses with multiple sarcoids were treated with both ointments. Of the 30 tumors treated with Aldara™ 27 tumors (90%) has so far responded with size reduction or total regression. The 3 tumors that didn´t respond to treatment were all fibroblastic sarcoids localized to the distal limbs on one horse. Of the 15 tumors treated with Xxterra™ 14 tumors (93%) has so far responded with size reduction or total regression. The tumor that didn´t respond to treatment was an occult sarcoid localized to the shoulder. In all the tumors that didn´t respond to treatment a change of medicine was made, after a treatment free period of at least 12 weeks, which immedately lead to a reduction in size. All the tumors has so far responded to at least one of the treatments. The preliminary results of these two types of treatments are encouraging, though the number of horses included in the study is small. An extended study, comprising more horses and longer periods of follow-up, is required to be able to corroborate these conclusions. Sarkoid utgör den vanligaste tumören världen över hos häst i klinisk verksamhet. Tumören är en benign, lokalt infiltrativ, proliferativ och inte sällan fibroblastisk hudneoplasm. Etiologin är inte helt klarlagd även om epidemiologin och tumörens kliniska beteende starkt indikerar en infektiös inblandning av bovint papillomvirus (BPV typ 1 eller 2). Dock krävs flera faktorer för att tumörerna skall kunna utvecklas. En genetisk predisposition, kopplat till gener inom major histocompability antigen complex (MHC), har identifierats, men även en ras-, ålders- och eventuellt könspredilektion. Ett bevisat samband mellan hudskada och uppkomst av sarkoider har även beskrivits. Hudtumörerna är ofta lokaliserade till områden där huden är tunnare, såsom ansikte, distala ben samt ventrala delarna av thorax och buk. Makroskopiskt finns 6 sarkoidtyper; ockult, nodulär, verrukös, fibroblastisk, blandad och malevolent. För att säkerställa diagnosen krävs dock en biopsi för histologisk undersökning. Utbudet av behandlingsmetoder är stort (kirurgi, kryokirurgi, hypertermi, strålning, cytostatika samt immunoterapi), men metoderna måste anpassas till tumörtyp, storlek, utbredning, lokalisation, tillgänglig utrustning samt omgivningens säkerhet. Sarkoider är även ökända för hög recidivrisk efter behandling. Föreliggande studie jämför och analyserar effekterna av Aldara™ och Xxterra™. Aldara™ är ett immunomodulerande läkemedel medan den exakta verkningsmekanismen för Xxterra™ ej är helt klarlagd. Tillverkarna av Xxterra™ menar dock att även detta läkemedel har en immunomodulerande verkan. Vid denna typ av behandlig stimuleras immunförsvaret lokalt för att få en reduktion av tumörceller samt virus. Syftet med studien är att hitta en enkel och effektiv behandlingsmetod med låg recidiv risk. I studien ingår 19 hästar med totalt 130 tumörer, varav 41 behandlas och resterande tumörer utgjorde obehandlade kontroller. Sjutton hästar med totalt 30 sarkoider behandlades med Aldara™ och 10 hästar med 15 sarkoider behandlades med Xxterra™. Åtta hästar med multipla sarkoider behandlades med båda preparaten. Av de 30 tumörer som behandlades med Aldara™ svarade 27 av tumörerna (90%), med storleksminskning eller total regression. De 3 tumörer som inte minskade i storlek var alla fibroblastiska sarkoider och lokaliserade till distala ben på en häst. Av de 15 tumörer som behandlades med Xxterra™ svarade 14 tumörer (93%) med storleksminskning eller total regression. Den tumör som inte svarade på behandling var en ockult sarkoid lokaliserad till bogen. Efter ett uppehåll på minst 12 veckor byttes preparat på de tumörer som inte svarade på behandling, vilket omgående ledde till storleksminskning. Alla tumörer har än så länge således svarat på minst en av behandlingarna. De preliminära resultaten för dessa typer av behandling verkar lovande, även om antalet inkluderade hästar är lågt. En mer omfattande studie med fler antal hästar och längre uppföljningsperiod krävs för att styrka slutsatserna. 2008-02-01 Other NonPeerReviewed application/pdf sv https://stud.epsilon.slu.se/11759/1/pettersson_c_171017.pdf Pettersson, Carina, 2008. Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM : en jämförande pilotstudie. UNSPECIFIED, Uppsala. Uppsala: (VH) > Dept. of Clinical Sciences (until 231231) <https://stud.epsilon.slu.se/view/divisions/OID-715.html> urn:nbn:se:slu:epsilon-s-7930 swe |
| spellingShingle | Miscellaneous animal disorders Pettersson, Carina Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM |
| title | Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM |
| title_full | Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM |
| title_fullStr | Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM |
| title_full_unstemmed | Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM |
| title_short | Utvärtes behandling av sarkoider på häst med Aldara TM eller Xxterra TM |
| title_sort | utvärtes behandling av sarkoider på häst med aldara tm eller xxterra tm |
| topic | Miscellaneous animal disorders |
| url | https://stud.epsilon.slu.se/11759/ https://stud.epsilon.slu.se/11759/ |